Is BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe?

Simply Wall St.01-09

In recent days, BD (Becton, Dickinson and Company) reported the first European prophylactic laparotomy reinforcement case in Greece using its Phasix™ Mesh, following expanded CE-marked approval, new ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602316084?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","is_english":true,"pubTime":"2026-01-09 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602316084","market":"sg","top_or_hot":-1,"title":"Is BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe?","media":"Simply Wall St.","content":"<div>\n<p>In recent days, BD (Becton, Dickinson and Company) reported the first European prophylactic laparotomy reinforcement case in Greece using its Phasix™ Mesh, following expanded CE-marked approval, new ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/is-bd-bdx-quietly-recasting-its-surgical-innovation-story-wi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 06:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/is-bd-bdx-quietly-recasting-its-surgical-innovation-story-wi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent days, BD (Becton, Dickinson and Company) reported the first European prophylactic laparotomy reinforcement case in Greece using its Phasix™ Mesh, following expanded CE-marked approval, new ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/is-bd-bdx-quietly-recasting-its-surgical-innovation-story-wi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4504","symbol_name":"桥水持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/is-bd-bdx-quietly-recasting-its-surgical-innovation-story-wi","article_id":"2602316084","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/is-bd-bdx-quietly-recasting-its-surgical-innovation-story-wi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602316084","pubTimestamp":1767911584,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent days, BD (Becton, Dickinson and Company) reported the first European prophylactic laparotomy reinforcement case in Greece using its Phasix™ Mesh, following expanded CE-marked approval, new product sizes, and broader availability across Europe and the U.K. for hernia prophylaxis indications.\nThis broader European indication, supported by ongoing PREVENT trial enrollment, points to a potentially wider clinical role for bioabsorbable mesh in high‑risk abdominal surgeries and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4504":"桥水持仓","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","BK7067":"生物科技","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BDX.AU":"BCAL DIAGNOSTICS LTD","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BDX":"碧迪医疗","BK4585":"ETF&股票定投概念","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","BK4082":"医疗保健设备","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC"},"translate_title":"BD(BDX)是否正在悄悄地重塑其外科创新故事，扩大Phasix补片在欧洲的使用？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX.AU":1.5,"BDX":1.5},"content_text":"In recent days, BD (Becton, Dickinson and Company) reported the first European prophylactic laparotomy reinforcement case in Greece using its Phasix™ Mesh, following expanded CE-marked approval, new product sizes, and broader availability across Europe and the U.K. for hernia prophylaxis indications. This broader European indication, supported by ongoing PREVENT trial enrollment, points to a potentially wider clinical role for bioabsorbable mesh in high‑risk abdominal surgeries and reinforces BD’s presence in advanced surgical solutions. We’ll now examine how this expanded European Phasix Mesh indication and clinical progress may reshape BD’s existing investment narrative and expectations. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.AdvertisementBecton Dickinson Investment Narrative RecapTo own BD, you need to believe in its role as a core, consumables‑heavy medical technology provider with ongoing demand for essential devices and higher value procedures. The expanded European indication for Phasix Mesh supports the advanced surgical solutions catalyst, but it is unlikely to outweigh near term execution risks around the planned Biosciences and Diagnostics separation or persistent trade and margin pressures. Among recent announcements, the board approved plan to separate the Biosciences and Diagnostic Solutions business stands out as most relevant. As BD highlights specialty platforms like Phasix Mesh and connected care, this proposed separation could sharpen the focus on higher margin medtech franchises while also increasing execution risk, stranded costs, and reliance on transitional service agreements at a time when new products are expected to underpin earnings progression. Yet investors should also be aware that continued tariff and trade headwinds could materially pressure margins and cash generation if... Read the full narrative on Becton Dickinson (it's free!)Becton Dickinson's narrative projects $24.7 billion revenue and $2.8 billion earnings by 2028. This requires 4.9% yearly revenue growth and about a $1.2 billion earnings increase from $1.6 billion today.Uncover how Becton Dickinson's forecasts yield a $204.83 fair value, in line with its current price.Exploring Other PerspectivesBDX 1-Year Stock Price Chart Five Simply Wall St Community valuations for BD cluster between about US$204.83 and US$326.35, underscoring how far apart individual expectations can be. Against this, BD’s tariff and trade exposure and planned business separation may influence how you interpret that spread and why it makes sense to review several different viewpoints.Explore 5 other fair value estimates on Becton Dickinson - why the stock might be worth as much as 59% more than the current price!Build Your Own Becton Dickinson NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Becton Dickinson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.Contemplating Other Strategies?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Uncover the next big thing with financially sound penny stocks that balance risk and reward.The latest GPUs need a type of rare earth metal called Terbium and there are only 39 companies in the world exploring or producing it. Find the list for free.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Becton Dickinson might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602316084","isCrawlerRequest":true}